Search Results - "Soo, Ross"

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies by Lim, Sun Min, Syn, Nicholas L., Cho, Byoung Chul, Soo, Ross A.

“…•Acquired resistance to EGFR targeted therapy can be EGFR-dependent or independent.•Third-generation EGFR TKIs are in various stages of clinical…”
Get full text

Can therapeutic drug monitoring of lorlatinib help us design the right CROWN? by Li, Molly, Soo, Ross A.

Get full text

De-novo and acquired resistance to immune checkpoint targeting by Syn, Nicholas L, Teng, Michele W L, Mok, Tony S K, Soo, Ross A

“…Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated…”
Get full text

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial by Shaw, Alice T, Solomon, Benjamin J, Chiari, Rita, Riely, Gregory J, Besse, Benjamin, Soo, Ross A, Kao, Steven, Lin, Chia-Chi, Bauer, Todd M, Clancy, Jill S, Thurm, Holger, Martini, Jean-Francois, Peltz, Gerson, Abbattista, Antonello, Li, Sherry, Ou, Sai-Hong Ignatius

“…Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most…”
Get full text

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer by Shaw, Alice T, Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Lin, Chia-Chi, Soo, Ross A, Riely, Gregory J, Ou, Sai-Hong Ignatius, Clancy, Jill S, Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M, Felip, Enriqueta, Martini, Jean-François

“…Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity…”
Get full text

Third generation EGFR TKIs: current data and future directions by Tan, Chee-Seng, Kumarakulasinghe, Nesaretnam Barr, Huang, Yi-Qing, Ang, Yvonne Li En, Choo, Joan Rou-En, Goh, Boon-Cher, Soo, Ross A

“…Acquired T790 M mutation is the commonest cause of resistance for advanced non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant…”
Get full text

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer by Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A

“…Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well…”
Get full text

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions by Soo, Ross A., Lim, Sun Min, Syn, Nicholas L., Teng, Rebecca, Soong, Richie, Mok, Tony S.K., Cho, Byoung Chul

“…•EGFR mutant NSCLC are more likely to have decreased PD-L1 expression.•Uninflamed tumor microenvironment may explain poor response to checkpoint…”
Get full text

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study by Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat, Seto, Takashi, James, Leonard P, Clancy, Jill S, Abbattista, Antonello, Martini, Jean-François, Chen, Joseph, Peltz, Gerson, Thurm, Holger, Ou, Sai-Hong Ignatius, Shaw, Alice T

“…Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study,…”
Get full text

Isolation and retrieval of circulating tumor cells using centrifugal forces by Hou, Han Wei, Warkiani, Majid Ebrahimi, Khoo, Bee Luan, Li, Zi Rui, Soo, Ross A., Tan, Daniel Shao-Weng, Lim, Wan-Teck, Han, Jongyoon, Bhagat, Ali Asgar S., Lim, Chwee Teck

“…Presence and frequency of rare circulating tumor cells (CTCs) in bloodstreams of cancer patients are pivotal to early cancer detection and treatment…”
Get full text

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies by Walsh, Robert J., Soo, Ross A.

“…The treatment landscape for patients with advanced non-small cell lung cancer has evolved greatly with the advent of immune checkpoint inhibitors. However,…”
Get full text

Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells by Khoo, Bee Luan, Warkiani, Majid Ebrahimi, Tan, Daniel Shao-Weng, Bhagat, Ali Asgar S, Irwin, Darryl, Lau, Dawn Pingxi, Lim, Alvin S T, Lim, Kiat Hon, Krisna, Sai Sakktee, Lim, Wan-Teck, Yap, Yoon Sim, Lee, Soo Chin, Soo, Ross A, Han, Jongyoon, Lim, Chwee Teck

“…Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to…”
Get full text

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study by Schuler, Martin, Cho, Byoung Chul, Sayehli, Cyrus Michael, Navarro, Alejandro, Soo, Ross A, Richly, Heike, Cassier, Philippe Alexandre, Tai, David, Penel, Nicolas, Nogova, Lucia, Park, Se Hoon, Schostak, Martin, Gajate, Pablo, Cathomas, Richard, Rajagopalan, Prabhu, Grevel, Joachim, Bender, Sebastian, Boix, Oliver, Nogai, Hendrik, Ocker, Matthias, Ellinghaus, Peter, Joerger, Markus

“…The clinical activity of fibroblast growth factor receptor (FGFR) inhibitors seems restricted to cancers harbouring rare FGFR genetic aberrations. In…”
Get full text

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) by Barr Kumarakulasinghe, Nesaretnam, Zanwijk, Nico van, Soo, Ross A.

“…Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated with chemotherapy alone, but a therapeutic plateau has been reached…”
Get full text

The promise of bispecific antibodies: Clinical applications and challenges by Lim, Sun Min, Pyo, Kyoung-Ho, Soo, Ross A, Cho, Byoung Chul

“…•Bispecific antibodies (BsAbs) are emerging therapeutic option in cancer patients.•BsAbs have unique formats to achieve their proposed function and clinical…”
Get full text

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy by Torlakovic, Emina, Lim, Hyun J., Adam, Julien, Barnes, Penny, Bigras, Gilbert, Chan, Anthony W. H., Cheung, Carol C., Chung, Jin-Haeng, Couture, Christian, Fiset, Pierre O., Fujimoto, Daichi, Han, Gang, Hirsch, Fred R., Ilie, Marius, Ionescu, Diana, Li, Chao, Munari, Enrico, Okuda, Katsuhiro, Ratcliffe, Marianne J., Rimm, David L., Ross, Catherine, Røge, Rasmus, Scheel, Andreas H., Soo, Ross A., Swanson, Paul E., Tretiakova, Maria, To, Ka F., Vainer, Gilad W., Wang, Hangjun, Xu, Zhaolin, Zielinski, Dirk, Tsao, Ming-Sound

“…Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different PD-L1 assays for immunotherapy…”
Get full text

Treatment options for EGFR mutant NSCLC with CNS involvement- can patients BLOOM with the use of Next Generation EGFR TKIs? by Tan, Chee-Seng, Cho, Byoung Chul, Soo, Ross A

“…Highlights • Cranial metastases are frequent sites of progression. • Surgery, stereotactic radiosurgery and/or WBRT has been the cornerstone of therapy. •…”
Get full text

Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer by Liu, Cuiliu, Xiang, Xiaoqiang, Han, Shuangqing, Lim, Hannah Ying, Li, Lingrui, Zhang, Xing, Ma, Zhaowu, Yang, Li, Guo, Shuliang, Soo, Ross, Ren, Boxu, Wang, Lingzhi, Goh, Boon Cher

“…Currently, early detection of lung cancer relies on the characterisation of images generated from computed tomography (CT). However, lung tissue biopsy, a…”
Get full text

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study by Solomon, Benjamin J, Bauer, Todd M, Mok, Tony S K, Liu, Geoffrey, Mazieres, Julien, de Marinis, Filippo, Goto, Yasushi, Kim, Dong-Wan, Wu, Yi-Long, Jassem, Jacek, López, Froylán López, Soo, Ross A, Shaw, Alice T, Polli, Anna, Messina, Rossella, Iadeluca, Laura, Toffalorio, Francesca, Felip, Enriqueta

“…After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free…”
Get full text

Nivolumab in NSCLC: latest evidence and clinical potential by Sundar, Raghav, Cho, Byoung-Chul, Brahmer, Julie R., Soo, Ross A.

“…New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player…”
Get full text